Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
10 September 2009 - 10:23PM
PR Newswire (US)
PinnacleCare To Offer Champions' Personalized Oncology Services To
Members Worldwide BALTIMORE, Sept. 10 /PRNewswire-FirstCall/ --
Champions Biotechnology, Inc. (OTC:CSBR) (BULLETIN BOARD: CSBR) , a
company whose personalized oncology services division assists
physicians by providing personalized treatment options for their
cancer patients, has entered into a collaboration agreement with
PinnacleCare, the pioneer and the leading private health advisory
company in the world. PinnacleCare will offer Champions'
personalized oncology services to its members worldwide who have
been diagnosed with cancer. Access to Champions' services will
benefit PinnacleCare members, and their physicians, in evaluating
personalized options to improve treatment outcomes. Champions'
services offered to PinnacleCare members will include: (i)
Personalized Oncology Panels(TM) comprised of world-renowned
experts assembled to assist the client's physician in determining
the optimal treatment, and (ii) Personalized Tumorgrafts(TM)
developed from fragments of the client's living tumor that are
surgically removed, propagated and tested to evaluate the
effectiveness of potential treatment drugs. Through this
collaboration, Champions will also offer PinnacleCare's health
advisory services to Champions clients. These services include: (i)
A PinnacleCare health advisor available globally and 24/7 answering
client questions, coordinating healthcare schedules, explaining
options, arranging treatments, assisting with individual medical
experts, staff, and bureaucracies, and available to attend
important appointments, and (ii) PinnacleCare Electronic Health
Records including collection, organization, and physician review of
client medical records, with all records kept up-to-date and
available instantly anywhere in the world for the client and
his/her expert healthcare team. "Champions Personalized Oncology
Panels and its Personalized Tumorgraft technology are exactly the
kind of cutting edge programs that PinnacleCare seeks for its
members," PinnacleCare Chief Medical Officer, Dr Miles Varn, said.
"We believe that the Champions approach to personalized oncology
will be of great benefit to our current and prospective members
through programs that evaluate treatment options based on the very
unique characteristics of each patient's cancer." "PinnacleCare and
Champions personalized oncology services complement each other like
hand and glove," said Doug Burkett, Ph.D., President of Champions
Biotechnology, Inc. "This collaboration will enable us to educate
many more physicians regarding our services and assist many more
individuals with cutting edge research to personalize their cancer
treatment. It will also enhance the individualized services for our
clients and provide instant access to state-of-the-art electronic
healthcare records for them and their expert healthcare team. We
look forward to working closely with PinnacleCare in this high
potential collaboration." About PinnacleCare PinnacleCare is the
world's leading private health advisory company, providing its
members with teams of dedicated advisors to manage family and
executive health care, access world-renowned specialists, provide
access to the world's most advanced medical research, coordinate
appointments, collect and maintain medical records with
PinnacleCare's Electronic Health Records solution and help members
enact proven preventive strategies for optimum longevity and
health. PinnacleCare serves 3,000 members worldwide and has offices
throughout the United States and London. For more information,
visit http://www.pinnaclecare.com/. About Champions Biotechnology,
Inc. Champions Biotechnology, Inc. is engaged in the development of
advanced preclinical platforms and tumor specific data to enhance
and accelerate the value of oncology drugs. The Company's
Preclinical Platform is a novel approach based upon the
implantation of primary human tumors in immune deficient mice
followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts(TM)) in a manner that preserves the biological
characteristics of the original human tumor. Early studies suggest
that unlike traditional xenografts, these Tumorgrafts closely
reflect human cancer biology and their response to drugs is
predictive of clinical outcomes in cancer patients. Champions
Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic
candidates. As drugs progress through early stage development, the
Company plans to sell, partner or license them to pharmaceutical
and/or biotechnology companies, as appropriate. The Company also
offers its predictive preclinical platform and tumor specific data
to physicians for personalized patient care and to companies for
evaluation of oncology drugs in models that integrate prognostic
testing with biomarker discovery. The personalized oncology
services division assists physicians by maximizing personalized
treatment options for their cancer patients through access to
expert medical information panels and development of personalized
Tumorgrafts from their patient's fresh tumor.
http://www.championsbiotechnology.com/
http://www.personalizedcancertreatment.com/ This press release
contains "forward-looking statements" (within the meaning of the
Private Securities Litigation Act of 1995) that inherently involve
risk and uncertainties. Champions Biotechnology generally uses
words such as "believe," "may," "could," "will," "intend,"
"expect," "anticipate," "plan," and similar expressions to identify
forward-looking statements. One should not place undue reliance on
these forward-looking statements. The Company's actual results
could differ materially from those anticipated in the
forward-looking statements for many unforeseen factors. See
Champions Biotechnology's Form 10-K for the fiscal year ended April
30, 2009 for a discussion of such risks, uncertainties and other
factors. Although the Company believes the expectations reflected
in the forward-looking statements are reasonable, they relate only
to events as of the date on which the statements are made, and
Champions Biotechnology's future results, levels of activity,
performance or achievements may not meet these expectations. The
Company does not intend to update any of the forward-looking
statements after the date of this press release to conform these
statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law.
DATASOURCE: Champions Biotechnology, Inc. CONTACT: The Investor
Relations Group, James Carbonara, +1-212-825-3210, Web Site:
http://www.championsbiotechnology.com/
Copyright